These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 31211217)

  • 1. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
    Riviere ME; Langbaum JB; Turner RS; Rinne JO; Sui Y; Cazorla P; Ricart J; Meneses K; Caputo A; Tariot PN; Reiman EM; Graf A
    Alzheimers Dement; 2024 Mar; 20(3):1839-1850. PubMed ID: 38145469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.
    Walsh T; Duff L; Riviere ME; Tariot PN; Doak K; Smith M; Borowsky B; Lopez Lopez C; Arratia PC; Liu F; Scholten I; Gordon D; Arbuckle J; Graf A; Quinn M; Ricart J; Langbaum JB
    J Prev Alzheimers Dis; 2023; 10(3):453-463. PubMed ID: 37357285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.
    Lopez Lopez C; Caputo A; Liu F; Riviere ME; Rouzade-Dominguez ML; Thomas RG; Langbaum JB; Lenz R; Reiman EM; Graf A; Tariot PN
    J Prev Alzheimers Dis; 2017; 4(4):242-246. PubMed ID: 29181489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical
    Tariot PN; Lopera F; Langbaum JB; Thomas RG; Hendrix S; Schneider LS; Rios-Romenets S; Giraldo M; Acosta N; Tobon C; Ramos C; Espinosa A; Cho W; Ward M; Clayton D; Friesenhahn M; Mackey H; Honigberg L; Sanabria Bohorquez S; Chen K; Walsh T; Langlois C; Reiman EM;
    Alzheimers Dement (N Y); 2018; 4():150-160. PubMed ID: 29955659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
    Caputo A; Racine A; Paule I; Tariot PN; Langbaum JB; Coello N; Riviere ME; Ryan JM; Lopez CL; Graf A; ;
    Alzheimers Res Ther; 2023 Mar; 15(1):45. PubMed ID: 36879340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort.
    Ihara R; Iwata A; Suzuki K; Ikeuchi T; Kuwano R; Iwatsubo T;
    Alzheimers Dement (N Y); 2018; 4():645-651. PubMed ID: 30511010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
    Neumann U; Ufer M; Jacobson LH; Rouzade-Dominguez ML; Huledal G; Kolly C; Lüönd RM; Machauer R; Veenstra SJ; Hurth K; Rueeger H; Tintelnot-Blomley M; Staufenbiel M; Shimshek DR; Perrot L; Frieauff W; Dubost V; Schiller H; Vogg B; Beltz K; Avrameas A; Kretz S; Pezous N; Rondeau JM; Beckmann N; Hartmann A; Vormfelde S; David OJ; Galli B; Ramos R; Graf A; Lopez Lopez C
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
    Xing F; Meng T; Therriault J; Luo J; Zhang H;
    J Integr Neurosci; 2021 Jun; 20(2):277-286. PubMed ID: 34258926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
    Zimmer JA; Shcherbinin S; Devous MD; Bragg SM; Selzler KJ; Wessels AM; Shering C; Mullen J; Landry J; Andersen SW; Downing AM; Fleisher AS; Svaldi DO; Sims JR
    Alzheimers Dement (N Y); 2021; 7(1):e12123. PubMed ID: 33614894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE inhibitors in clinical development for the treatment of Alzheimer's disease.
    Panza F; Lozupone M; Solfrizzi V; Sardone R; Piccininni C; Dibello V; Stallone R; Giannelli G; Bellomo A; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Expert Rev Neurother; 2018 Nov; 18(11):847-857. PubMed ID: 30277096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.